Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter

Tadashi Komata, Yasuko Kondo, Shoji Koga, Seiji Kondo, Tadashi Komata, Seiji Kondo, Satoshi Hirohata, Tadashi Komata, Yasuko Kondo, Takao Kanzawa, Isabelle M. Germano, Seiji Kondo, Hideaki Sumiyoshi, Srinivasa M. Srinivasula, Emad S. Alnemri, Barbara P. Barna, Masahiro Takakura, Masaki Inoue, Satoru Kyo, Jerry W. Shay

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Because the apoptotic pathway is often disrupted in tumor cells, its genetic restoration is a very attractive approach for the treatment of tumors. To treat malignant gliomas with this approach, it would be preferred to restrict induction of apoptosis to tumor cells by establishing a tumor-specific expression system. Telomerase is an attractive target because the vast majority of malignant gliomas have telomerase activity whereas normal brain cells do not. Activation of telomerase is tightly regulated at the transcriptional level of the telomerase catalytic subunit [human telomerase reverse transcriptase, (hTERT)]. Therefore, we hypothesized that using a hTERT promoter-driven vector system, an apoptosis-inducible gene may be preferentially restricted to telomerase- or hTERT-positive tumor cells. In this study, we constructed an expression vector consisting of the constitutively active caspase-6 (rev-caspase-6) under the hTERT promoter (hTERT/rev-caspase-6) and then investigated its antitumor effect on malignant glioma cells. The rationale for using the rev-caspase-6 gene is because it induces apoptosis independent of the initiator caspases. We demonstrated that the hTERT/rev-caspase-6 construct induced apoptosis in hTERT-positive malignant glioma cells, but not in hTERT-negative astrocytes, fibroblasts, and alternative lengthening of telomeres cells. In addition, the growth of s.c. tumors in nude mice was significantly suppressed by the treatment with hTERT/rev-caspase-6 construct. The present results strongly suggest that the telomerase-specific transfer of the rev-caspase-6 gene under the hTERT promoter is a novel targeting approach for the treatment of malignant gliomas.

Original languageEnglish
Pages (from-to)5796-5802
Number of pages7
JournalCancer Research
Volume61
Issue number15
Publication statusPublished - Aug 1 2001
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter'. Together they form a unique fingerprint.

  • Cite this

    Komata, T., Kondo, Y., Koga, S., Kondo, S., Komata, T., Kondo, S., Hirohata, S., Komata, T., Kondo, Y., Kanzawa, T., Germano, I. M., Kondo, S., Sumiyoshi, H., Srinivasula, S. M., Alnemri, E. S., Barna, B. P., Takakura, M., Inoue, M., Kyo, S., & Shay, J. W. (2001). Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Research, 61(15), 5796-5802.